论文信息 - A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer. - 字舞流文

A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer.

J. Marshall | L. Weiner | M. Pishvaian | R. Slack | J. Hwang | J. Brody | A. He | K. Dorsch-Vogel | A. Hankin | T. McAndrew | A. Witkiewicz | D. Kuda